UY39264A - Compuestos de dihidroquinolinsulfonamida de ciclopropilo - Google Patents

Compuestos de dihidroquinolinsulfonamida de ciclopropilo

Info

Publication number
UY39264A
UY39264A UY0001039264A UY39264A UY39264A UY 39264 A UY39264 A UY 39264A UY 0001039264 A UY0001039264 A UY 0001039264A UY 39264 A UY39264 A UY 39264A UY 39264 A UY39264 A UY 39264A
Authority
UY
Uruguay
Prior art keywords
compounds
dihydroquinolinsulfonamide
cyclopropyl
formula
present
Prior art date
Application number
UY0001039264A
Other languages
English (en)
Inventor
C Milgram Benjamin
E Marx Isaac
H Cherney Alan
Wei Zhao
John Stellwagen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY39264A publication Critical patent/UY39264A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de Fórmula I,un enantiómero, diastereoisómero, atropisómero del mismo, una mezcla de los mismos, o una sal farmacéuticamente aceptable del mismo, que inhibe los canales de sodio activados por voltaje, en particular NaV1.7. Los compuestos son útiles para el tratamiento de enfermedades asociadas con la actividad de los canales de sodio tales como trastornos del dolor, tos y picazón. También se proporcionan composiciones farmacéuticas que contienen los compuestos de la presente invención. También se proporciona además una preparación atropi-selectiva de dichos compuestos de Fórmula (I), y un producto intermedio de los mismos.
UY0001039264A 2020-06-10 2021-06-10 Compuestos de dihidroquinolinsulfonamida de ciclopropilo UY39264A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063036999P 2020-06-10 2020-06-10

Publications (1)

Publication Number Publication Date
UY39264A true UY39264A (es) 2021-12-31

Family

ID=76845312

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039264A UY39264A (es) 2020-06-10 2021-06-10 Compuestos de dihidroquinolinsulfonamida de ciclopropilo

Country Status (10)

Country Link
US (2) US11807634B2 (es)
EP (1) EP4164748A1 (es)
JP (1) JP2021195367A (es)
AR (1) AR122593A1 (es)
AU (1) AU2021289741A1 (es)
CA (1) CA3183814A1 (es)
MX (1) MX2022015622A (es)
TW (1) TW202214587A (es)
UY (1) UY39264A (es)
WO (1) WO2021252818A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117813302A (zh) 2021-06-04 2024-04-02 沃泰克斯药物股份有限公司 经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
JP2024520643A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン
AU2022286438A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
BR112023025264A2 (pt) 2021-06-04 2024-02-20 Vertex Pharma Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida
AU2022285758A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
US20230373925A1 (en) 2022-04-22 2023-11-23 Vertex Pharma Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4412994A (en) 1980-04-24 1983-11-01 Interx Research Corporation Mannich-base hydroxamic acid prodrugs, compositions and use
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
TN2017000376A1 (en) * 2015-03-02 2019-01-16 Amgen Inc Bicyclic ketone sulfonamide compounds
EA038286B1 (ru) 2015-12-18 2021-08-04 Амген Инк. Соединения алкилдигидрохинолинсульфонамида
US10729684B2 (en) * 2015-12-18 2020-08-04 Amgen Inc. Alkynyl dihydroquinoline sulfonamide compounds

Also Published As

Publication number Publication date
JP2021195367A (ja) 2021-12-27
MX2022015622A (es) 2023-01-11
TW202214587A (zh) 2022-04-16
WO2021252818A1 (en) 2021-12-16
AR122593A1 (es) 2022-09-21
EP4164748A1 (en) 2023-04-19
US11807634B2 (en) 2023-11-07
CA3183814A1 (en) 2021-12-16
AU2021289741A1 (en) 2022-12-22
US20210387977A1 (en) 2021-12-16
US20230234948A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
UY39264A (es) Compuestos de dihidroquinolinsulfonamida de ciclopropilo
UY39263A (es) Compuestos de dihidroquinolinsulfonamida de ciclobutilo
BR112022012641A2 (pt) Compostos tricíclicos substituídos
CL2017002153A1 (es) Compuestos bicíclicos de sulfonamida cetona
CL2022000619A1 (es) Oxinitruro de piridina, método para su preparación y uso de este
MX2022006475A (es) Compuestos triciclicos sustituidos.
ECSP21030066A (es) 2-amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
DOP2022000290A (es) 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8
MA45223A (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
AR035502A1 (es) Un compuesto derivado de tipo fenil-sustituido cetona como antagonistas del receptor de prostaglandina i2 (ip), una composicion farmaceutica que comprende a dicho compuesto, uso del mismo y un proceso para preparar dicho compuesto
ES2179353T3 (es) Antagonistas muscarinicos.
CO2020011852A2 (es) Inhibidores de canales receptores de potencial transitorio de oxadiazol
UY26728A1 (es) Derivados de la benzocicloalquilenilamina como antagonistas de los receptores muscarínicos
CO2022008606A2 (es) Derivados de piridopirimidinona como antagonistas de ahr
UY26919A1 (es) Derivados de la quinazolina como antagonistas adrenérgicos alfa - 1
CO2023008949A2 (es) Forma cristalina de tolebrutinib, método de preparación y uso de la misma
CO2018007436A2 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
AR127470A1 (es) Inhibidores de lrrk2
CO2021014223A2 (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios
BR112022009533A2 (pt) Composição farmacêutica para administração oral, e, método para preparar uma composição farmacêutica
UY39799A (es) Compuestos de pirrolil–sulfonamida
JP2020509043A (ja) カンナビノイドアゴニストによる認知症の治療
PE20001487A1 (es) 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-oles sustituidos con n-(5-fenil-tetrahidrofuranil) metilo y n-(6-fenil-tetrahidropiranil) metilo; procedimientos para prepararlos y su empleo como composiciones farmaceuticas
AR126260A1 (es) Moduladores de nlrp3